There is a major race between three drug companies to release their new weight loss drug to the market. All three new potential diet drugs are showing good results in tests. It is being reported now that these diet drugs are also showing promise to help with other health issues such as high blood pressure, cholesterol, triglycerides and blood-sugar control.

A new weight-loss drug appears to also reverse the progress of diabetes and cholesterol. The drug, so far called fatostatin as stating drugs are the best-known for cholesterol control, could be a three-way magic bullet against obesity, cholesterol, and diabetes.

The Food and Drug Administration is investigating the reports a potential side effect of Alli is liver damage. The only FDA approved over-the-counter weight loss drug, Alli and its prescription formula, Xenical has been the subject of an FDA investigation due claims the drug in Alli and Xanical, Orlistat is the cause of liver damage in over 30 cases through out the world.

Alli, a half-strength version of the prescription-only Xenical, which interferes with the body's ability to digest fat, and Appesat, a seaweed extract, which is said to swell up and trick the brain into thinking the stomach is full, will cost £1-a-day and £29.95 for 50 capsules respectively.

The Union-Tribune reports that "Arena Pharmaceuticals failed to impress analysts and investors yesterday when it revealed the results of its first phase 3 clinical trial for the drug lorcaserin."

The U.S. FDA is warning consumers nationwide not to purchase or consume more than 25 different weight loss pills because they contain undeclared, active pharmaceutical ingredients that may put consumers’ health at risk.

Obese patients with a specific genetic make-up lose more weight when taking the weight loss drug sibutramine and undergoing behavioral therapy compared to those without this genetic make-up, reports a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses.

More than 60 percent of American women are overweight, with nearly a third falling into the category of obese and at greater risk of cancer, heart disease and diabetes. Until now, there has been no safe, long-term medical remedy that tackles unwanted weight gain.

Glaxo Smith Kline's Alliâ„¢, the first FDA-approved over-the-counter weight loss pill, hits shelves nationwide this Friday. Whether or not it succeeds depends a large part on its multilingual, multi-million dollar marketing campaign. A new study by Wharton professors and doctors at the University of Pennsylvania School of Medicine provides applicable new insight into consumer thinking about health remedies.